Inhaling the inert gas xenon could protect against neurodegeneration and offset some of the key features of Alzheimer’s disease, preclinical studies suggest. The findings in mice reveal a novel therapeutic application for this noble gas, which has been used as an anesthetic in humans since the mid-20th century and as…

Research led by New York University Grossman School of Medicine and the Institute of Medical Biochemistry Leopoldo de Meis in Brazil has identified two biomarkers in the blood that decrease as cognitive decline and Alzheimer’s disease progresses. The researchers found that the protein acetyl-L-carnitine was reduced in both men and…

New evidence of a “waste canal system” in the human brain has been uncovered by researchers from Saint Michael’s College and the University of Vermont. Part of their research was on neurodegeneration in Central American wandering spiders. This “canal” system internalizes waste from healthy neurons. The team found that it…

The presence of a specific type of fat, known as visceral fat, in midlife can predict risk for Alzheimer’s disease in later years, according to research led by Washington University School of Medicine. Obesity between the age of 40 and 60 years is known to be linked to increased risk…

Researchers at the University of California (UC) Irvine have conducted a transcriptomics analysis of Alzheimer’s disease, looking at the spatial differences in gene expression found across the brains of patients with early-stage and late-stage Alzheimer’s, as well as Alzheimer’s disease in Down syndrome. Their results, published in Nature Genetics, uncovered…

A study conducted by researchers at the Johns Hopkins University School of Medicine and Tufts University School of Medicine, shows that a synthetic THC, known as dronabinol, has been shown to effectively reduce agitation in Alzheimer’s disease (AD) patients. The findings, presented at the International Psychogeriatric Association conference in Buenos…

An international team of researchers has developed a promising new drug that works on both major Tau protein aggregation “hotspots,” a key driver of neurodegeneration including Alzheimer’s disease. The novel peptide inhibitor, RI-AG03, has demonstrated efficacy in preventing Tau aggregation in both laboratory and fruit fly studies, while showing no…

Researchers from the Medical Research Council Laboratory of Molecular Biology (MRC LMB) in Cambridge, England and the UK Dementia Research Institute (UK DRI) at the University of Cambridge have developed new potential therapies that selectively remove the aggregated tau tangles to treat Alzheimer’s disease (AD). Their work, detailed in two…

A novel technique developed by researchers at the Washington University (WashU) School of Medicine has allowed them to study aged neurons in the lab without the need for a brain biopsy. The technique has identified aspects of the genome of cells in the development of late-onset Alzheimer’s disease (AD) that…

A research team led by the Broad Institute of MIT and Harvard has mapped gene expression across six areas of the brain linked to Alzheimer’s disease using a single-cell transcriptomics approach. Writing in Nature, the authors explain that they were able to map 1.3 million cells from 283 post-mortem brain…

Dementia is an early sign of Alzheimer’s disease, but not all patients with it will go on to develop the progressive brain disorder for which there is no cure. Early detection, however, allows for the treatment of symptoms and the building support and medical care teams. Now, a team of…

The Davos Alzheimer’s Collaborative (DAC) announced that it will collaborate with health systems in Germany, the U.K., Japan, the U.S., and the Netherlands to leverage blood biomarkers and confirmatory diagnostic testing to for early identification of Alzheimer’s disease and related dementias (ADRD). The goal of the Accurate Diagnosis project is…

A multinational research collaboration led by researchers at the University of Kentucky Sanders-Brown Center on Aging have used long-read RNA sequencing to identify 53 new RNA isoforms in medically relevant genes related to Alzheimer’s disease (AD) and other neurodegenerative diseases. Their study, published in Nature Biotechnology, is part of an…

Icahn School of Medicine at Mount Sinai researchers report that they have identified a novel method to potentially slow or even halt progression of Alzheimer’s disease (AD) by manipulating cellular interactions of protein around myeloid plaques. The new findings, published in the journal Nature Neuroscience, focuses on the role of…

Research led by Columbia University in New York has uncovered a genetic variant in the gene encoding fibronectin 1 (FN1) that protects against Alzheimer’s disease in carriers of the high risk APOE4 allele. It appears to do this by preventing excessive build-up of fibronectin in the blood brain barrier, something…